Cargando…

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action

The clinical application of HIV fusion inhibitor, enfuvirtide (T20), was limited mainly because of its short half-life. Here we designed and synthesized two PEGylated C34 peptides, PEG2kC34 and PEG5kC34, with the PEG chain length of 2 and 5 kDa, respectively, and evaluated their anti-HIV-1 activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chen, Cheng, Shuihong, Zhang, Yuanyuan, Ding, Yibo, Chong, Huihui, Xing, Hui, Jiang, Shibo, Li, Xuebing, Ma, Liying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784077/ https://www.ncbi.nlm.nih.gov/pubmed/31480738 http://dx.doi.org/10.3390/v11090811

Ejemplares similares

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
por: Cheng, Shuihong, et al.
Publicado: (2016)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
por: Xu, Wei, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides
por: Gomara, Maria J., et al.
Publicado: (2019)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor
por: Chong, Huihui, et al.
Publicado: (2012)

Early Steps of HIV-1 Fusion Define the Sensitivity to Inhibitory Peptides That Block 6-Helix Bundle Formation
por: Miyauchi, Kosuke, et al.
Publicado: (2009)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK
por: Chong, Huihui, et al.
Publicado: (2014)

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
por: Zhang, Hongwei, et al.
Publicado: (2016)

A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life
por: Duan, Qianyu, et al.
Publicado: (2022)

The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis
por: Huang, Ruijing, et al.
Publicado: (2018)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Alpha-Glucosidase Inhibitory Peptides: Sources, Preparations, Identifications, and Action Mechanisms
por: Lu, Han, et al.
Publicado: (2023)

Identification and Characterization of Dipeptidyl Peptidase-IV Inhibitory Peptides from Oat Proteins
por: Wang, Wei, et al.
Publicado: (2022)

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile
por: Su, Shan, et al.
Publicado: (2017)

Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41
por: Muñoz-Barroso, Isabel, et al.
Publicado: (1998)

Two modes of fusogenic action for influenza virus fusion peptide
por: Michalski, Michal, et al.
Publicado: (2023)

HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2013)

Development of Long-Acting Human Adrenomedullin Fc-Fusion Proteins
por: Nagata, Sayaka, et al.
Publicado: (2022)

Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides
por: Mathieu, Cyrille, et al.
Publicado: (2017)

Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection
por: Reynard, Olivier, et al.
Publicado: (2022)

Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection
por: Reynard, Olivier, et al.
Publicado: (2022)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Conjugation of Cholesterol to HIV-1 Fusion Inhibitor C34 Increases Peptide-Membrane Interactions Potentiating Its Action
por: Hollmann, Axel, et al.
Publicado: (2013)

Correction: HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2014)

A long-acting C-natriuretic peptide for achondroplasia
por: Schneider, Eric L., et al.
Publicado: (2022)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy
por: Ouyang, Yabo, et al.
Publicado: (2017)

Fabrication of Antimicrobial Peptide-Loaded PLGA/Chitosan Composite Microspheres for Long-Acting Bacterial Resistance
por: Li, Yuanyuan, et al.
Publicado: (2017)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015)

Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity
por: Wan, Chao, et al.
Publicado: (2013)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

Membrane-Anchored HIV-1 N-Heptad Repeat Peptides Are Highly Potent Cell Fusion Inhibitors via an Altered Mode of Action
por: Wexler-Cohen, Yael, et al.
Publicado: (2009)

Line tension at lipid phase boundaries as driving force for HIV fusion peptide-mediated fusion
por: Yang, Sung-Tae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3sa5m3c276bt5ig32og7q7i5os